Home > Journals > European Journal of Oral and Maxillofacial Surgery > Past Issues > European Journal of Oral and Maxillofacial Surgery 2018 December;2(3) > European Journal of Oral and Maxillofacial Surgery 2018 December;2(3):43-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

European Journal of Oral and Maxillofacial Surgery 2018 December;2(3):43-6

DOI: 10.23736/S2532-3466.18.00143-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Photodynamic therapy with Photolon® photosensitizer in patients with oral leukoplakia: a single-center experience

Dmitry A. TZERKOVSKY

Laboratory of Photodynamic Therapy and Hyperthermia, N.N. Alexandrov National Cancer Center, Lesnoy, Belarus



BACKGROUND: Oral leukoplakia is the most common potentially malignant disorder that may transform into oral carcinoma. At that moment, an increase of interest in the use of the laser technologies in treatment of various forms of oral leukoplakia is noted. One of the possible ways of solving this problem is photodynamic therapy. In a number of cancer centers (Europe, Asia, and South America), studies are under way to evaluate the effectiveness of photodynamic therapy of oral leukoplakia with various photosensitizers (5-aminolevulinic acid, methylene blue and toluidine blue). The aim of present study is to evaluate tolerability and results of photodynamic therapy for patients with oral leukoplakia.
METHODS: This work was carried out on 60 patients with morphologically verified leukoplakia of the oral mucosa. Chlorine-based Photolon® photosensitizer (Belmedpreparaty, Minsk, Belarus) was administered intravenously at doses of 2-2.5 mg/kg. Photoirradiation session was performed 2.5-3 hours after administration with exposure doses 30-100 J/cm2. The effectiveness of treatment was assessed 1-3 months after treatment sessions by clinical data.
RESULTS: No adverse reaction during the photosensitizer administration and photoirradiation were observed. Complete regression of pathological foci recorded in 93.3% of cases and partial in 6.7%. The follow-up period varied from 1 to 36 months.
CONCLUSIONS: Photodynamic therapy is a well-tolerated and effective method of treating patients with this pre-tumor pathology.


KEY WORDS: Oral leukoplakia - Photosensitizing agents - Chlorine - Photochemotherapy

top of page